Health Care & Life Sciences » Biotechnology | Revance Therapeutics Inc.

Revance Therapeutics Inc. | Ownership

Companies that own Revance Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Wellington Management Co. LLP
3,782,587
10.24%
-31,447
0.02%
06/30/2018
Franklin Advisers, Inc.
2,631,936
7.13%
-518,726
0.05%
06/30/2018
BlackRock Fund Advisors
2,595,213
7.03%
385,574
0%
06/30/2018
JPMorgan Investment Management, Inc.
2,246,604
6.08%
187,382
0.02%
06/30/2018
ArrowMark Colorado Holdings LLC
1,804,275
4.88%
68,576
0.44%
06/30/2018
Capital Research & Management Co. (World Investors)
1,435,000
3.89%
1,435,000
0.01%
06/30/2018
The Vanguard Group, Inc.
1,412,758
3.83%
141,858
0%
06/30/2018
AllianceBernstein LP
1,310,053
3.55%
170,942
0.02%
06/30/2018
Jennison Associates LLC
1,131,960
3.06%
-351,077
0.03%
06/30/2018
JPMorgan Asset Management (UK) Ltd.
1,110,819
3.01%
34,025
0.03%
06/30/2018

About Revance Therapeutics

View Profile
Address
7555 Gateway Boulevard
Newark California 94560
United States
Employees -
Website http://www.revance.com
Updated 07/08/2019
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.